Skip to main content
OpenTrials

Clinical trial condition

Diffuse Large B-cell Lymphoma

Explore clinical trials studying Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

213 public trials 54 recruiting studies
Refine in advanced search Browse all conditions

Diffuse Large B-cell Lymphoma trial results

Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT01741792

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Universitätsmedizin Göttingen, Germany
  • Universitätsklinikum des Saarlandes Homburg, Germany
  • Universitätsklinikum Schleswig Holstein Kiel, Germany
  • Klinikum der Johannes-Gutenberg Universität Mainz, Germany
View Trial Details
Completed

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

NCT00607854

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Service d'hématologie - CHU de Besançon Besançon, France
  • Service des maladies du sang - Hôpital Haut-Lévêque - avenue de magellan Bordeaux - Pessac, France
  • Service d'hématologie - CHU Hôtel Dieu Clermont-Ferrand Clermont-Ferrand, France
  • Service de médecine nucléaire - Centre de Lutte contre le Cancer de la Région Auvergne Jean Perrin Clermont-Ferrand, France
View Trial Details
Completed

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

NCT01562990

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • AZ Sint Jan Bruges, Belgium
  • University Hospital Gent Ghent, Belgium
  • CHU Mont-Godinne Yvoir, Belgium
  • Hôpital Henri Mondor Créteil, France
View Trial Details
Completed

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00831597

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Pharmatech Oncology Study Site Beverly Hills, California, United States
  • Pharmatech Oncology Study Site Fountain Valley, California, United States
  • Pharmatech Oncology Study Site Oxnard, California, United States
  • Pharmatech Oncology Study Site Washington D.C., District of Columbia, United States
View all 33 locations
View Trial Details
Completed

Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma

NCT01369784

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Hospital de Elda Elda, Alicante, Spain
  • H. U. Germans Trias i Pujol Badalona, Barcelona, Spain
  • Hospital Clinic i Provincial Barcelona, Spain
  • Hospital del Mar Barcelona, Spain
View all 56 locations
View Trial Details
Completed

Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT01470456

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Investigational Site Number 040002 Graz, Austria
  • Investigational Site Number 250004 Créteil, France
  • Investigational Site Number 250009 Dijon, France
  • Investigational Site Number 250006 Lille, France
View all 13 locations
View Trial Details

Related conditions